Home > Boards > Free Zone > Health and Sciences >

Biotech Values

RSS Feed
      Hide Sticky   Hide Intro
Moderator: DewDiligence Assistants: Biowatch
Search This Board: 
Last Post: 3/19/2019 6:35:48 PM - Followers: 1411 - Board type: Free - Posts Today: 36

Biotech Values is a forum for discussing 
all facets of biotech investing with an emphasis
on fundamental analysis and avoiding scams.
We generally do not discuss microcap stocks.

Compilations
FDA Calendar
Biotech Buyouts/Premiums

Biotech Acronyms
'Way Back' Archive

PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
PostSubject
#224192  Sticky Note PPD is nasty, but would someone go through jbog 03/19/19 06:08:09 PM
#224182  Sticky Note MRKR 10K is worth reading: rfj1862 03/19/19 12:15:18 PM
#224181  Sticky Note ENTA is a sleeper entrant in the HBV DewDiligence 03/19/19 12:10:15 PM
#224168  Sticky Note ...the key is [EOLS] are not racing to DewDiligence 03/19/19 09:47:21 AM
#224112  Sticky Note Re: ADXS financing and news-flow speculation DewDiligence 03/17/19 08:14:04 PM
#224095  Sticky Note RVNC—Eylea is indeed a pertinent benchmark for the DewDiligence 03/15/19 05:55:06 PM
#224193   The 60-hour infusion at a specially licensed site DewDiligence 03/19/19 06:35:48 PM
#224192   PPD is nasty, but would someone go through jbog 03/19/19 06:08:09 PM
#224191   FDA approves SAGE’s Zulresso (brexanolone) for postpartum depression: DewDiligence 03/19/19 05:55:44 PM
#224190   re: MRKR bladerunner1717 03/19/19 03:48:46 PM
#224189   AFMD +7% on ROCK milestone payment from Roche. semi_infinite 03/19/19 02:54:17 PM
#224188   Well, how much cash did ADXS forfeit by DewDiligence 03/19/19 02:46:52 PM
#224186   How is the cashless swap only for a ignatiusrielly35 03/19/19 02:21:31 PM
#224185   …with two more competitors being added over the DewDiligence 03/19/19 01:52:53 PM
#224184   I have looked at the company and wonder rfj1862 03/19/19 01:29:08 PM
#224183   I have looked at the company and wonder n4807g 03/19/19 01:13:44 PM
#224182   MRKR 10K is worth reading: rfj1862 03/19/19 12:15:18 PM
#224181   ENTA is a sleeper entrant in the HBV DewDiligence 03/19/19 12:10:15 PM
#224180   Arrowhead looks interesting if overvalued. Their HBV program rfj1862 03/19/19 12:05:18 PM
#224179   None of the new HBV agents is in DewDiligence 03/19/19 11:58:05 AM
#224178   The most notable takeaway (IMO) is the Roche rfj1862 03/19/19 11:42:36 AM
#224177   Re: Jefferies HBV forum yesterday DewDiligence 03/19/19 11:28:23 AM
#224176   The RT002 FDA label for glabellar lines might DewDiligence 03/19/19 11:12:18 AM
#224175   << duration is given as an approximate range, jmkobers 03/19/19 11:00:29 AM
#224174   warning - this board is going to turn rfj1862 03/19/19 10:25:51 AM
#224173   Quote: ...”the key is [EOLS] are not racing to biotech_researcher 03/19/19 10:21:33 AM
#224172   Right—see the EOLS CC excerpt in #msg-147635889. DewDiligence 03/19/19 10:15:13 AM
#224171   EOLS - From Minx at Investor Village: WID 03/19/19 10:13:18 AM
#224170   EOLS—The need to wait for publication of their DewDiligence 03/19/19 10:05:43 AM
#224169   they said they would launch in spring prior dewophile 03/19/19 10:01:55 AM
#224168   ...the key is [EOLS] are not racing to DewDiligence 03/19/19 09:47:21 AM
#224167   What do you make of EOLS' not having DewDiligence 03/19/19 09:40:45 AM
#224166   Re: RVNC /specification of duration in label DewDiligence 03/19/19 09:39:51 AM
#224165   Re: Jeuveau pricing DewDiligence 03/19/19 09:27:42 AM
#224164   On the CC, management acknowledged that the actual dewophile 03/19/19 09:18:58 AM
#224163   yes i saw that dewophile 03/19/19 09:16:15 AM
#224162   Re: Jeuveau list price DewDiligence 03/19/19 08:40:10 AM
#224161   The concise duration spec in the Botox FDA DewDiligence 03/19/19 08:34:39 AM
#224160   RVNC/EOLS more color on pricing from the cc: dewophile 03/19/19 08:22:04 AM
#224159   warning - this board is going to turn dewophile 03/19/19 07:59:40 AM
#224158   AMRN: Further viewpoints/opinions/data from Reduce-It trial, presented at north40000 03/19/19 02:34:35 AM
#224157   AMRN Vascepa was panned by a respected UCSF iwfal 03/18/19 08:19:15 PM
#224156   Any thoughts on Mgta? ronpopeil 03/18/19 08:11:15 PM
#224155   Dew. .. I should add ( I see Whalatane 03/18/19 08:05:05 PM
#224154   Alphaeon won't have to worry about dilution unless DewDiligence 03/18/19 07:40:58 PM
#224153   I'm sure EOLS will manage the company completely jbog 03/18/19 07:29:48 PM
#224152   Right. The PR is in one of the DewDiligence 03/18/19 07:13:19 PM
#224151   It seems ELOS reached outside the box to jbog 03/18/19 07:06:25 PM
#224150   Thanks (eom). DewDiligence 03/18/19 05:58:43 PM
#224149   See: https://investorshub.advfn.com/boards/replies.aspx?msg=147624581 GrthzGd 03/18/19 05:56:05 PM
#224148   I feel like this has become the RVNC DewDiligence 03/18/19 05:43:56 PM
#224147   What did she say about Vascepa? DewDiligence 03/18/19 05:40:25 PM
#224146   Iwfal. No worries. Just me venting Repatha Whalatane 03/18/19 05:37:54 PM
#224145   PTE -15% on SEC investigation: DewDiligence 03/18/19 05:27:48 PM
#224144   Price targets from sell-side analysts have little or DewDiligence 03/18/19 05:19:50 PM
#224143   EOLS—Jeuveau's US list price is $610 per 100U DewDiligence 03/18/19 05:13:32 PM
PostSubject